Alerts will be sent to your verified email
Verify EmailINDSWFTLAB
|
Ind-Swift Lab.
|
Jagsonpal Pharma
|
Lincoln Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Total reactor capacity
|
700.0 kL | n/a | n/a |
|
DMF Filingsby API
|
474.0 . | n/a | n/a |
|
R&D as a % of Total Sales
|
2.9 % | n/a | 1.88 % |
|
Financials
|
|||
|
5 yr Average ROE
|
14.7 % | 16.01 % | 15.1 % |
|
5yr average Equity Multiplier
|
2.17 | 1.27 | 1.26 |
|
5yr Average Asset Turnover Ratio
|
0.66 | 1.09 | 0.82 |
|
5yr Avg Net Profit Margin
|
16.17 % | 12.08 % | 14.59 % |
|
Price to Book
|
0.91 | 4.88 | 1.67 |
|
P/E
|
4.77 | 30.2 | 13.6 |
|
5yr Avg Cash Conversion Cycle
|
15.71 Days | 2.39 Days | -6.41 Days |
|
Inventory Days
|
103.91 Days | 37.29 Days | 43.91 Days |
|
Days Receivable
|
105.66 Days | 15.63 Days | 91.75 Days |
|
Days Payable
|
107.02 Days | 59.94 Days | 128.38 Days |
|
5yr Average Interest Coverage Ratio
|
21.19 | 66.99 | 63.13 |
|
5yr Avg ROCE
|
12.09 % | 18.99 % | 19.81 % |
|
5yr Avg Operating Profit Margin
|
14.94 % | 13.23 % | 18.35 % |
|
5 yr average Debt to Equity
|
0.91 | 0.01 | 0.0 |
|
5yr CAGR Net Profit
|
n/a | 26.54 % | 5.76 % |
|
5yr Average Return on Assets
|
11.49 % | 12.71 % | 11.92 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
39.5 % | 67.39 % | 49.78 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-2.5 % | -1.32 % | 3.44 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Ind-Swift Lab.
|
Jagsonpal Pharma
|
Lincoln Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
-
|
-
|